Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Enzalutamide in Severe Hepatic Impairment
NCT02138162Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Pharmacokinetics of enzalutamide at Day 50 and Pharmacokinetics of N-desmethyl enzalutamide (M2) at Day 50. Started Aug 2013; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02138162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138162.